Unlock stock picks and a broker-level newsfeed that powers Wall Street.

XETRA - Delayed Quote EUR

Danaher Corporation (DAP.DE)

172.20
-3.76
(-2.14%)
At close: April 24 at 5:35:44 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Steven M. Rales Co-Founder & Chairman -- -- 1951
Mr. Rainer M. Blair President, CEO & Director 4.55M 9.66M 1964
Mr. Mitchell P. Rales Co-Founder & Director -- -- 1957
Mr. Matthew R. McGrew CFO & Executive VP 2.38M 7.36M 1972
Dr. Jose-Carlos Gutierrez-Ramos Ph.D. Senior VP & Chief Science Officer 2.02M -- 1962
Mr. Brian W. Ellis J.D. Senior VP, General Counsel & Chief Compliance Officer 1.8M -- 1967
Ms. Georgeann F. Couchara Senior Vice President of Human Resources 1.71M 398.08k 1977
Mr. Christopher M. Bouda VP & Chief Accounting Officer -- -- --
Mr. John Bedford Vice President of Investor Relations -- -- --
Mr. James F. O'Reilly Senior VP, Deputy General Counsel, Secretary & Chief Sustainability Officer -- -- --

Danaher Corporation

2200 Pennsylvania Avenue N.W.
Suite 800W
Washington, DC 20037-1701
United States
202 828 0850 https://www.danaher.com
Sector: 
Healthcare
Full Time Employees: 
61,000

Description

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.

Corporate Governance

Danaher Corporation’s ISS Governance QualityScore as of April 1, 2025 is 7. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 2; Compensation: 2.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

July 21, 2025 at 12:30 PM UTC - July 25, 2025 at 12:30 PM UTC

Danaher Corporation Earnings Date

Recent Events

March 28, 2025 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers